hSCRO Committee Meetings and Deadlines

All New research protocol submissions which require hSCRO review
Addition of new cell lines or materials as listed under “Activities that required hSCRO review” if materials are not from federally/state-funded established cell repositories and/or provenance documentation has not been previously reviewed by UCI hSCRO.
Modifications containing substantial changes to the specific aims or design of the study.
In vivo transplantation of pluripotent stem cells, cells of fetal origin or neural stem cells (with the exception of the addition of teratoma assays which qualify for expedited review).
HSCRO Full Committee meeting schedule (deadline for submission and corresponding meeting dates)

Proposed changes in research related to activities that do not significantly affect the assessment of the ethical and social issues, and do not substantially change the specific aims or design of the study.
Addition of teratoma assay standard in vivo procedur
Continuing Review of research approved by the hSCRO Full unless the research has had any instance of noncompliance or unanticipated problems during the previous year of approval

Addition or deletion of personnel as long as key research personnel are not deleted from the study team.
Updates in study locations and cell storage locations.
Deletions of cell lines.
Additions of registered cell lines, cell lines/ materials that have been previously approved by UCI hSCRO or cell lines obtained from source material that has previously been verified by UCI hSCRO including standard fluorescent reporter lines (such as GFP). Note: federally/state-funded cell established repositories (such as the NIH registry) are considered already verified sources.